Welcome, Guest. Please login or register.
July 18, 2024, 03:53:31 pm

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 203
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 57
Total: 57


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Early Trial of Experimental Hepatitis B Agent Sets Stage for Cure Research  (Read 7071 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
An experimental hepatitis B virus (HBV) treatment, the core protein allosteric modulator RO7049389, showed robust activity against the virus and was safe and well tolerated, MedPage Today reports. These findings support further study of the agent as a possible component of a hep B cure regimen.

Presenting their findings at the 52nd International Liver Congress in Paris, researchers conducted a two-part study of RO7049389. The first part examined the safety, tolerability and pharmacokinetics (how the drug is metabolized) of the agent. The second part gave a variety of single doses of the drug, ranging from 150 to 2,000 milligrams, to five groups of people as well as multiple doses, ranging from 200 to 800 mg, to another five groups of people who did not have hep B. The second part of the study also gave twice daily doses of 200 mg of RO7049389 for 28 days to individuals with chronic hep B who had not been treated before.   



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.